Nordicus Partners Corporation (NORD)
OTCMKTS · Delayed Price · Currency is USD
3.490
+0.740 (26.91%)
Sep 5, 2025, 4:00 PM EDT
Nordicus Partners Revenue
Nordicus Partners had revenue of $5.00K in the twelve months ending June 30, 2025, up 100.00% year-over-year. In the fiscal year ending March 31, 2025, Nordicus Partners had annual revenue of $5.00K with 100.00% growth.
Revenue
5.00K
Revenue Growth
+100.00%
P/S Ratio
12,509.14
Revenue / Employee
n/a
Employees
n/a
Market Cap
62.55M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 5.00K | 2.50K | 100.00% |
| Mar 31, 2024 | 2.50K | - | - |
| Mar 31, 2023 | - | - | - |
| Mar 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Kuber Resources | 5.99M |
| Steel Partners Holdings L.P. | 2.07B |
| Siem Industries | 224.73M |
| Entrepreneur Universe Bright Group | 4.86M |
| Paul Mueller Company | 264.04M |
| Mestek | 299.77M |
| Sino Green Land | 1.47M |
| Scope Industries | 77.00M |
Nordicus Partners News
- 6 days ago - Nordicus Partners Corporation Applies to Uplist to the Nasdaq Capital Market - GlobeNewsWire
- 4 weeks ago - Nordicus Partners Corporation Appoints Three New Members to Its Board of Directors - GlobeNewsWire
- 4 months ago - Nord Anglia Education's collaboration with IMG Academy creates exciting new opportunities for student performance, leadership, and wellbeing - Benzinga
- 5 months ago - Bio-Convert Receives Positive Feedback from The Danish Medicine Agency (DKMA) on its Lead Drug Candidate, QR-02 for Oral Leukoplakia - GlobeNewsWire
- 5 months ago - Orocidin's QR-01 Shows Positive Results in Treating Periodontitis in Dogs - GlobeNewsWire
- 7 months ago - Orocidin and Syngene Partner to Accelerate Biotech Innovation - GlobeNewsWire
- 7 months ago - Orocidin QR-01 Shows a Good Safety Profile in Preclinical Toxicity Study - GlobeNewsWire
- 7 months ago - Bio-Convert Develops QR-02, a Potential Breakthrough in the Treatment of Oral Leukoplakia - GlobeNewsWire